🔗 Share this article

A shadow economy for unlicensed slimming medications is being driven by social media fitness personalities and vendors on communication apps, according to recent findings.

Investigational Treatment Gaining Traction Online

Retatrutide, which is still in clinical trials, is being promoted by online personalities for its alleged fat-burning properties. Viewers are encouraged to message these profiles directly for supplier links, while also receiving discount codes.

Active Commerce on Social Networks

Additionally, a robust trade exists on messaging services, where groups with thousands of participants share “before and after” photos, injection guides and claims of next-day UK delivery. Vendors market the substance there before directing buyers to other platforms for transactions.

Learning About Retatrutide

This medication is an investigational injectable created by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could help patients lose up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being promoted online as the successor to Ozempic.

Healthcare Experts Express Concerns

However, physicians and chemists have cautions that the sale of what is still an unlicensed medication in the UK is a cause for concern and could lead to users injecting substances of unknown origin.

Some experts stated the demand for the experimental drug could be connected to the rising price of licensed weight loss products such as Mounjaro.

Legal Status and Enforcement

Marketing retatrutide on social media or messaging apps is prohibited in the UK, as it is an unapproved drug that must not be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.

Some content creators attempt to circumvent the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still breach pharmaceutical, marketing, and consumer regulations, risking penalties, prosecution or imprisonment.

Service Response and Content Removal

Based on the social media company, the platform has taken down violative content and prohibited related hashtags and search suggestions. The company said it was committed to maintaining the service safe and investing in strengthening compliance measures.

Online Trading Operations

Research also discovered groups with up to nine thousand participants marketing the experimental drug using the platform's built-in search feature, which functions like a public directory. Entering “retatrutide” instantly displays groups with numerous of members, populated with photos of slimming results, positive testimonials and step-by-step instructions for preparing or injecting at residence.

After minutes of joining one community, a seller shared WhatsApp details, where the majority of purchases occur. The vendor sent an guidebook and promised delivery within two days. When asked whether the substance was authentic, one vendor said: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. Not one inquired about weight, health issues or previous experience.

Product Details and Costs

Within these communities, posts display black plastic packages with postal service stickers, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, prepared at home with purified liquid, or ready-to-use pens usually sold at £160 for 20 milligrams. When asked how much time a pen should be used, sellers give contradictory answers varying between a several days to “depends on your body”.

Service Moderation and Safety Measures

A representative for Telegram said it regularly monitored harmful content on its platform including material that encouraged the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“People are injecting substances they cannot confirm. Although the research behind this drug is valid, these digital products may not contain what they claim,” stated a pharmacy expert, the head of pharmacy at Chemist4U.

Dr Crystal Wyllie of an online medical service linked the surge in demand to recent price rises for authorized weight-loss drugs such as Mounjaro. “With costs rising, patients are using online platforms. But fake injections are extremely risky. You cannot know what’s inside or whether the environment they were produced in was clean,” she said.

Her staff has already encountered patients harmed by self-injection from unverified suppliers. “We recognize the disappointment, but buying from messaging apps or WhatsApp is gambling with your well-being,” said the doctor. “These substances could be impure or improperly measured.”

Manufacturer Position

A representative from the pharmaceutical company said the substance was in phase 3 research studies and had not been reviewed or authorized by any regulatory agency globally. “Consequently at this time no one can market [it] for personal consumption,” they said, adding that any item “falsely representing itself as a Lilly investigational substance not yet authorized … may subject patients to possibly serious medical dangers”.